Figure 4

Represents the in vivo performance study of gliclazide loaded PLGA SGNCs formulation, (a) Pharmacodynamic responses of pure gliclazide, placebo and optimized formulation, SGNCF1 on type II diabetic rats; (b) Plasma mean gliclazide concentration–time curves after single oral dosing of pure gliclazide and optimized formulation, SGNCF1 on type 2diabetic rats; (c) Represents Pharmacokinetic-Pharmacodynamic correlation plot of gliclazide loaded PLGA SGNCs formulation on type 2 diabetic rats. Each point represents the mean ± SD of the data obtained from the experiments (n = 6).